Published in final edited form as:

Cell Mol Neurobiol. 2018 April ; 38(3): 769–774. doi:10.1007/s10571-017-0514-0.

Chromosome 21-encoded microRNAs (mRNAs) – impact on Down's syndrome and trisomy-21 linked disease

PN Alexandrov¹, ME Percy^{2,3,4}, and WJ Lukiw^{5,6,7}

¹Russian Academy of Medical Sciences, Moscow 113152, Russian Federation

²Department of Physiology, University of Toronto, Toronto, Canada

³Department of Obstetrics and Gynecology, Toronto, Canada

⁴Surrey Place Centre, Toronto, Canada

⁵LSU Neuroscience Center, Louisiana State University Health Science Center, New Orleans LA 70112, USA

⁶Department of Ophthalmology, Louisiana State University Health Science Center, New Orleans LA 70112, USA

⁷Department of Neurology, Louisiana State University Health Science Center, New Orleans LA 70112, USA

Abstract

Down's syndrome (DS; also known as trisomy 21; T21) is caused by a triplication of all or part of human chromosome 21 (chr21). DS is the most common genetic cause of intellectual disability attributable to a naturally-occurring imbalance in gene dosage. DS incurs huge medical, healthcare and socioeconomic costs and there are as yet no effective treatments for this incapacitating human neurogenetic disorder. There is a remarkable *wide variability* in the '*phenotypic spectrum*' associated with DS, the progression of symptoms and the age of DS onset fluctuate, and there are further variabilities of the biophysical nature of the chr21 duplication. Besides the cognitive disruptions and dementia in DS patients other serious health problems such as atherosclerosis, altered lipogenesis, Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), autoimmune disease, various cancers including lymphoma, leukemia, glioma and glioblastoma, status epilepticus, congenital heart disease, hypotonia, manic depression, prostate cancer, Usher syndrome, motor disorders, Hirschsprung disease, and various physical anomalies such as early aging occur at elevated frequencies, and all are part of the Down syndrome '*phenotypic spectrum*'. This communication will review the genetic link between these fore-mentioned diseases and a small group of just 5 stress-associated microRNAs (miRNAs) - that

Corresponding author: Walter J. Lukiw, BS, MS, PhD, LSU Neuroscience Center, Louisiana State University Health Sciences Center, 2020 Gravier Street, Suite 904, New Orleans LA 70112-2272 USA, wlukiw@lsuhsc.edu.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author Contributions: PNA, MEP and WJL discussed the genomic data and scientific implications of these ideas; WJL researched and wrote this paper; the authors are sincerely grateful to colleagues and collaborators for helpful discussions and for sharing unpublished data.

include let-7c, miRNA-99a, miRNA125b, miRNA-155 and miRNA-802 – encoded and clustered on the long arm of human chr21 and spanning the chr21q21.1-chr21q21.3 region.

Keywords

42 amino acid amyloid-beta (A β 42) peptide; Alzheimer's disease (AD); Down's Syndrome; microRNA (miRNA); small non-coding RNAs (sncRNAs); systemic inflammation

Introduction

Linking the chr21 gene dosage imbalance in DS with the considerable variability of the DS phenotype has been an elusive goal in the study of trisomy 21 activity, function, genetics and epigenetics (Hattori et al., 2000; Antonarakis 2017; Castro et al., 2017; Max Plank Institute 2017; NCBI 2017; Vega Genome Browser 54: Homo sapiens 2017). Interestingly a single copy gene encoding the 770 amino acid beta amyloid precursor protein (β APP), the precursor to the 42 amino acid amyloid beta (A β 42) peptide that accumulates in both familial and sporadic AD and DS brains is encoded at chr21q21.3; virtually all DS patients exhibit AD-type pathological change as they age, including progressive A β 42 peptide accumulation (Castro et al., 2017a; Hithersay et al., 2017). Evidence associating a specific gene or chr21 domain to a particular phenotype has been restricted and relatively limited in chr21 genomic studies (Hattori et al., 2000; Antonarakis 2017; Castro et al., 2017; Hithersay et al., 2017). Another understudied and perhaps underappreciated area of trisomy 21 gene triplication are the potential contribution of chr21-encoded micro RNAs (miRNAs), their DS-associated increase in abundance (because of the extra chr21 copy - a gene dosage effect), and their enormous potential to shape and regulate the DS transcriptome, and hence alter both pathogenic and global gene expression patterns (Hattori et al., 2000; Li et al., 2012; Ghorai et al., 2014; Hithersay et al., 2017).

miRNAs represent a novel and intriguing group of endogenous small non-protein-coding RNAs (sncRNAs) that are evolutionary conserved and widely distributed amongst all species so far studied in both the plant and animal kingdoms (Guo et al., 2010; Eichhorn et al., 2014; Hruska-Plochan et al., 2015; Zhao et al., 2015; Hill and Lukiw 2016; Liu et al., 2017). Interestingly a single miRNA can regulate multiple target genes dispersed throughout all somatic chromosomes, indicating that miRNAs may regulate multiple signaling pathways and participate in numerous physiological and pathological processes. The major mode of action of these sncRNAs is to interact, via base-pair complementarity, with the 3'-untranslated region (3'-UTR) of their target messenger RNAs (mRNAs), and in doing so decrease the expression of that particular target mRNA, and hence act as negative regulators of target gene expression. Ribosome profiling and RNA sequencing have shown that up-regulated miRNAs act predominantly to decrease their target mRNA levels, and miRNA-mediated destabilization of mRNAs is the main reason for the observed reductions in gene expression as are characteristic of both AD and DS brains (Guo et al., 2010; Codocedo et al., 2016; Liu et al., 2017).

Consisting of 48 million base pairs (Mbp) and representing ~1.5% of total cellular DNA, chr21 contains a relatively low number of identified genes (~225), for example, compared

with the 545 genes reported for the 49 Mbp chromosome 22 (chr22; Hattori et al., 2000). Equally under-represented is the small number of just 5 microRNAs (miRNAs) encoded and clustered around the long arm of chr21 spanning the chr21q21.1-chr21q21.3 region (compared to the ~46 miRNAs encoded on chr22; Dunham et al., 1999; “Vega Genome Browser 54: Homo sapiens 2017; http://atlasgeneticsoncology.org/Indexbychrom/idxg_22.html). Chr21 encoded miRNAs include let-7c, miRNA-99a, miRNA125b, miRNA-155 and miRNA-802. Together specific members of this small miRNA family **(i)** have been found to be readily detectable in control brains and significantly up-regulated in both AD and DS brains (Zhao et al., 2015; Hill et al., 2016); **(ii)** are observed to be up-regulated more than gene-dosage effects alone would predict (Li et al., 2012); **(iii)** includes a subset of micro RNAs including miRNA-99a, miRNA125b and miRNA-155 that are inducible and under NF-kB regulatory control (Lukiw 2007; Lukiw 2012; Prasad 2017; unpublished observations); and **(iv)** are known to down-regulate the expression of key innate-immune regulatory and anti-inflammatory genes in AD and/or DS (Pogue et al., 2010; Lukiw et al., 2012; Maciotta et al., 2013; Hill et al., 2015; Hill and Lukiw 2016; Nadim et al., 2017). For example, gene dosage mediated increases in the chr21-encoded miRNA-155 have been shown in part to down-regulate the expression of complement factor H (CFH), an important soluble, innate-immune regulatory glycoprotein in AD and DS tissues and in primary brain cell models of AD, and be centrally involved in pathogenic signaling pathways that include inflammatory neurodegeneration (Li et al., 2012; Lukiw 2012; Zhao et al., 2015; Hill and Lukiw 2016).

Concluding Remarks

As research into the molecular-genetics of Down's syndrome (Trisomy 21) progresses, more and more neurological (and non-neurological) diseases have been shown to be significantly linked to the Trisomy 21 phenotype. This ‘Short Communications’ paper provides 4 novel findings hitherto unrecognized or undocumented in the research field involving the molecular-genetics of Trisomy 21: **(i)** for the first time we point out that the 5 microRNAs encoded on the extra copy of chromosome 21 in Downs syndrome have potential to regulate the expression of over 3600 genes (see Table 1 and text); **(ii)** largely due to the containment of 5 microRNAs encoded on chromosome 21, and the fact that DS is the most common genetic cause of intellectual disability attributable to a naturally-occurring imbalance in gene dosage; this communication provides the first example of what was classically considered a neurological-developmental-dementing disorder as also a serious contributor to the development of disease in other major organ systems including the heart, lung, blood, bladder, prostate, thyroid and circulatory system, GI tract, as well as predisposition to many types of cancer; **(iii)** for the first time we point out the hitherto unappreciated regulatory potential of chromosome 21 in the development of a very broad clinical spectrum of potentially fatal human disease; and **(iv)** that further study and analysis of these chr21-encoded miRNAs, their mRNA interactions and induction of pathogenic biological pathways provides a greatly expanded list of potential therapeutic targets which would ultimately define the basis for more effective treatments in the clinical management of secondary maladies associated with development of chr21-linked disease.

Perhaps most importantly, miRNA-mRNA integration mapping, in depth RNA sequence analysis using complementarity algorithms and bioinformatics evaluation indicate that these five chr21-encoded miRNAs have the remarkable capacity to potentially regulate the expression approximately 3630 protein-coding genes (Table 1). This rather large number of protein-coding genes targeted by chr21-encoded miRNAs and the chr21 miRNA-mediated potential down-regulation of vast numbers of mRNAs may in part explain the tremendous diversity and complexity of human maladies associated with DS. This knowledge should be useful in targeting miRNA-mediated molecular mechanisms that cause or modify the development and propagation of different DS phenotypes. For example, employing anti-miRNA-based therapeutic strategies directed toward a single or a few chr21 specific miRNAs: (i) could be of therapeutic use in the restoration of essential and homeostatic mRNA and gene expression patterns in DS patients; and/or (ii) may ultimately provide more effective treatments in the clinical management of ancillary maladies associated with the Trisomy 21 phenotype (Lukiw 2013; Antonarakis 2017; Castro et al., 2017; Zhao et al., 2017).

Acknowledgments

This research work was presented in part at the Alzheimer Association International Congress 2016 (AAIC 2016) Annual conference 21-27 July 2016 in Toronto CANADA and at the 13th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2017) 29 March – 2 April in Vienna AUSTRIA. Thanks are also extended to the many neuropathologists, physicians and researchers of the US, Canada and Europe for helpful discussions and who have provided high quality, short post-mortem interval (PMI) human CNS, extracted tissue fractions and/or bioinformatics data for scientific analysis and study and to Drs. Christoff Eicken, Chris Hebel, Kyle Navel, Aileen Pogue and Darlene Guillot for expert technical assistance, organization and medical artwork. Research on the pro-inflammatory and pathogenic signaling in the Lukiw laboratory involving the innate-immune response, neuroinflammation and amyloidogenesis in AD, PD, DS, retinal and prion disease and in other neurological diseases was supported through an unrestricted grant to the LSU Eye Center from Research to Prevent Blindness (RPB); the Louisiana Biotechnology Research Network (LBRN) and NIH grants NEI EY006311, NIA AG18031 and NIA AG038834.

References

- Antonarakis SE. Down syndrome and the complexity of genome dosage imbalance. *Nat Rev Genet Disease Mechanisms*. 2017; 18:147–163. DOI: 10.1038/nrg.2016.154
- Asim A, Kumar A, Muthuswamy S, Jain S, Agarwal S. Down syndrome: an insight of the disease. *J Biomed Sci*. 2015; 22:41.doi: 10.1186/s12929-015-0138-y [PubMed: 26062604]
- Bofill-De Ros X, Santos M, Vila-Casadesús M, Villanueva E, Andreu N, Dierssen M, et al. Genome-wide miR-155 and miR-802 target gene identification in the hippocampus of Ts65Dn Down syndrome mouse model by miRNA sponges. *BMC Genomics*. 2015; 16:907.doi: 10.1186/s12864-015-2160-6 [PubMed: 26546125]
- Cao ZQ, Shen Z, Huang WY. MicroRNA-802p promotes osteosarcoma cell proliferation by targeting p27. *Asian Pac J Cancer Prev*. 2013; 14:7081–4. [PubMed: 24460254]
- Castro P, Zaman S, Holland A. Alzheimer's disease in people with Down's syndrome: the prospects for and the challenges of developing preventative treatments. *J Neurol*. 2017; 264:804–813. DOI: 10.1007/s00415-016-8308-8 [PubMed: 27778163]
- Cappuzzo F, Sacconi A, Landi L, Ludovini V, Biagioni F, D'Incecco A, et al. microRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies. *Clin Colorectal Cancer*. 2014; 13:37–45.e4. DOI: 10.1016/j.clcc.2013.11.006 [PubMed: 24503111]
- Church RJ, Otieno M, McDuffie JE, Singh B, Sonee M, Hall L, et al. Beyond miR-122: identification of microRNA alterations in blood during a time course of hepatobiliary injury and biliary hyperplasia. *Toxicol Sci*. 2016; 150:3–14. DOI: 10.1093/toxsci/kfv260 [PubMed: 26614776]

- Codocedo JF, Ríos JA, Godoy JA, Inestrosa NC. Are microRNAs the molecular link between metabolic syndrome and Alzheimer's disease? *Mol Neurobiol.* 2016; 53:2320–2338. DOI: 10.1007/s12035-015-9201-7 [PubMed: 25976367]
- Crowley EH, Arena S, Lamba S, Di Nicolantonio F, Bardelli A. Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels *Hum. Mutat.* 2014; 35:208–214.
- Devier DJ, Lovera JF, Lukiw WJ. Increase in NF- κ B-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro-inflammatory neurodegeneration. *Front Mol Neurosci.* 2015; 8:5. 2015. doi: 10.3389/fnmol.2015.00005 [PubMed: 25784854]
- Dunham I, Shimizu N, Roe BA, Chisoe S, Hunt AR, Collins JE, et al. The DNA sequence of human chromosome 22. *Nature.* 1999; 402:489–495. [PubMed: 10591208]
- Eichhorn SW, Guo H, McGeary SE, Rodriguez-Mías RA, Shin C, Baek D, et al. mRNA destabilization is the dominant effect of mammalian microRNAs by the time substantial repression ensues. *Mol Cell.* 2014; 56:104–115. DOI: 10.1016/j.molcel.2014.08.028 [PubMed: 25263593]
- Feng M, Luo X, Gu C, Li Y, Zhu X, Fei J. Systematic analysis of berberine-induced signaling pathway between miRNA clusters and mRNAs and identification of mir-99a ~ 125b cluster function by seed-targeting inhibitors in multiple myeloma cells. *RNA Biol.* 2015; 12:82–91. DOI: 10.1080/15476286.2015.1017219 [PubMed: 25826415]
- Ferlazzo E, Sueri C, Elia M, D'Agostino T, Aguglia U. Reflex seizures in a patient with Angelman syndrome and trisomy 21. *Neurol Sci.* 2016; 37:1373–1374. DOI: 10.1007/s10072-016-2547-4 [PubMed: 26972081]
- Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. *Nature.* 2010; 466:835–840. DOI: 10.1038/nature09267 [PubMed: 20703300]
- Ghorai A, Ghosh U. miRNA gene counts in chromosomes vary widely in a species and biogenesis of miRNA largely depends on transcription or post-transcriptional processing of coding genes. *Front Genet.* 2014; 5:100. doi: 10.3389/fgene.2014.00100 [PubMed: 24808907]
- Hithersay R, Hamburg S, Knight B, Strydom A. Cognitive decline and dementia in Down syndrome. *Curr Opin Psychiatry.* 2017 Mar; 30(2):102–107. 2017. DOI: 10.1097/YCO.0000000000000307 [PubMed: 28009725]
- Hattori M, Fujiyama A, Taylor TD, Watanabe H, Yada T, Park HS, et al. Chr21 mapping and sequencing consortium. The DNA sequence of human chromosome 21. *Nature.* 2000; 405:311–319. [PubMed: 10830953]
- Higuchi C, Nakatsuka A, Eguchi J, Teshigawara S, Kanzaki M, Katayama A, et al. Identification of circulating miR-101, miR-375 and miR-802 as biomarkers for type 2 diabetes. *Metabolism.* 2015; 64:489–97. DOI: 10.1016/j.metabol.2014.12.003 [PubMed: 25726255]
- Hill JM, Pogue AI, Lukiw WJ. Pathogenic microRNAs common to brain and retinal degeneration; recent observations in Alzheimer's disease and age-related macular degeneration. *Front Neurol.* 2015; 6:232. doi: 10.3389/fneur.2015.00232 [PubMed: 26579072]
- Hill JM, Lukiw WJ. MicroRNA (miRNA)-mediated pathogenetic signaling in Alzheimer's disease (AD). *Neurochem Res.* 2016; 41:96–100. DOI: 10.1007/s11064-015-1734-7 [PubMed: 26441222]
- Hou B, Ishinaga H, Midorikawa K, Shah SA, Nakamura S, Hiraku Y, et al. Circulating microRNAs as novel prognosis biomarkers for head and neck squamous cell carcinoma. *Cancer Biol Ther.* 2015; 16:1042–6. DOI: 10.1080/15384047.2015.1045692 [PubMed: 25950115]
- Hruska-Plochan M, Li B, Kyburz D, Krützfeld J, Landmesser U, Aguzzi A, Polymenidou M. New and emerging roles of small RNAs in neurodegeneration, muscle, cardiovascular and inflammatory diseases. *Swiss Med Wkly.* 2015; 145:w14192. doi: 10.4414/smww.2015.14192 [PubMed: 26376442]
- Huang HG, Luo X, Wu S, Jian B. miR-99a inhibits cell proliferation and tumorigenesis through targeting mTOR in human anaplastic thyroid cancer. *Asian Pac J Cancer Prev.* 2015; 16:4937–4944. http://atlasgeneticsoncology.org/Indexbychrom/idxg_22.html; Retrieved 16 May 2017. <http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/>; Retrieved 17 May 2017. <http://www.genecards.org/cgi-bin/carddisp.pl?gene=Let-7c&keywords=Let-7c>; Retrieved May 16, 2017 <http://www.genecards.org/cgi-bin/carddisp.pl?gene=MIR99a&keywords=mir-99a>; Retrieved May 16, 2017. <http://www.genecards.org/cgi-bin/carddisp.pl?gene=MIR125b&keywords=mir-125b>;

Retrieved May 16, 2017. <http://www.genecards.org/cgi-bin/carddisp.pl?gene=MIR155&keywords=mir-155>; Retrieved May 16, 2017. <http://www.genecards.org/cgi-bin/carddisp.pl?gene=MIR802&keywords=mir-802>; Retrieved May 16, 2017. [PubMed: 26163618]

Jiang R, Li Y, Zhang A, Wang B, Xu Y, Xu W, et al. The acquisition of cancer stem cell-like properties and neoplastic transformation of human keratinocytes induced by arsenite involves epigenetic silencing of let-7c via Ras/NF-kappaB. *Toxicol. Lett.* 2014; 227:91–98.

Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. *Genes Dev.* 2007; 21:1025–30. [PubMed: 17437991]

Li YY, Alexandrov PN, Pogue AI, Zhao Y, Bhattacharjee S, Lukiw WJ. miRNA-155 upregulation and complement factor H deficits in Down's syndrome. *Neuroreport.* 2012; 23:168–73. DOI: 10.1097/WNR.0b013e32834f4eb4 [PubMed: 22182977]

Li N, Qin ZB. Inflammation-induced miR-802 promotes cell proliferation in cholesteatoma. *Biotechnol Lett.* 2014; 36:1753–9. DOI: 10.1007/s10529-014-1545-y [PubMed: 24867318]

Liu EY, Cali CP, Lee EB. RNA metabolism in neurodegenerative disease. *Dis Model Mech.* 2017; 10:509–518. DOI: 10.1242/dmm.028613 [PubMed: 28468937]

Lu ZL, Wu JJ, Jiang WL, Xiao JH, Tao KZ, Ma L, et al. microRNA-155 promotes the pathogenesis of experimental colitis by repressing SHIP-1 expression. *World J Gastroenterol.* 2017; 23:976–985. DOI: 10.3748/wjg.v23.i6.976 [PubMed: 28246471]

Lukiw WJ. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. *Neuroreport.* 2007; 18:297–300. [PubMed: 17314675]

Lukiw WJ. NF- κ B-regulated micro RNAs (miRNAs) in primary human brain cells. *Exp Neurol.* 2012; 235:484–490. DOI: 10.1016/j.expneurol.2011.11.022 [PubMed: 22138609]

Lukiw WJ, Surjyadipta B, Dua P, Alexandrov PN. Common micro RNAs (miRNAs) target complement factor H (CFH) regulation in Alzheimer's disease (AD) and in age-related macular degeneration (AMD). *Int J Biochem Mol Biol.* 2012; 3:105–16. [PubMed: 22509485]

Lukiw WJ. Antagonism of NF- κ B-up-regulated micro RNAs (miRNAs) in sporadic Alzheimer's disease (AD)-anti-NF- κ B vs. anti-miRNA strategies. *Front Genet.* 2013; 4:77.doi: 10.3389/fgene.2013.00077 [PubMed: 23641256]

Lutz P, M'haimid M, Pohlmann A, Lehmann J, Jansen C, Schierwagen R, et al. microRNA-155 is upregulated in ascites in patients with spontaneous bacterial peritonitis. *Sci Rep.* 2017; 7:40556.doi: 10.1038/srep40556

Maciotta S, Meregalli M, Torrente Y. The involvement of microRNAs in neurodegenerative diseases. *Front Cell Neurosci.* 2013; 7:265.doi: 10.3389/fncel.2013.00265 [PubMed: 24391543]

Mikamori M, Yamada D, Eguchi H, Hasegawa S, Kishimoto T, Tomimaru Y, et al. microRNA-155 controls exosome synthesis and promotes gemcitabine resistance in pancreatic ductal adenocarcinoma. *Sci Rep.* 2017; 7:42339.doi: 10.1038/srep42339 [PubMed: 28198398]

Max Planck Institute for Molecular Genetics. <http://chr21.molgen.mpg.de/projects/proteomics.html>; data retrieved 16 May 2017

Moss J, Nelson L, Powis L, Waite J, Richards C, Oliver C. A comparative study of sociability in Angelman, Cornelia de Lange, Fragile X, Down and Rubinstein Taybi Syndromes and autism spectrum disorder. *Am J Intellect Dev Disabil.* 2016; 121:465–486. [PubMed: 27802104]

National Center for Biotechnology Information. Map Viewer. www.ncbi.nlm.nih.gov; data retrieved 16 May 2017

Nadim WD, Simion V, Benedetti H, Pichon C, Baril P, Morisset-Lopez S. microRNAs in neurocognitive dysfunctions: new molecular targets for pharmacological treatments? *Curr Neuropharmacol.* 2017; 15:260–275. [PubMed: 27396304]

Pogue AI, Cui JG, Li YY, Zhao Y, Culicchia F, Lukiw WJ. Micro RNA-125b (miRNA-125b) function in astrogliosis and glial cell proliferation. *Neurosci Lett.* 2010; 476:18–22. DOI: 10.1016/j.neulet.2010.03.054 [PubMed: 20347935]

Prasad KN. Oxidative stress and pro-inflammatory cytokines may act as one of the signals for regulating microRNAs expression in Alzheimer's disease. *Mech Ageing Dev.* 2017; 162:63–71. DOI: 10.1016/j.mad.2016.12.003 [PubMed: 27964992]

- Regazzo G, Terrenato I, Spagnuolo M, Carosi M, Cognetti G, Cicchillitti L, et al. A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas. *J Exp Clin Cancer Res*. 2016; 35:124.doi: 10.1186/s13046-016-0393-0 [PubMed: 27476114]
- Risbud RM, Porter BE. Changes in miRNA expression in the whole hippocampus and hippocampal synapto-neurosome fraction following pilocarpine induced status epilepticus. *PLoS One*. 2013; 8:e53464.doi: 10.1371/journal.pone.0053464 [PubMed: 23308228]
- Sethi P, Lukiw WJ. Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer's disease temporal lobe neocortex. *Neurosci Lett*. 2009; 459:100–104. [PubMed: 19406203]
- Siew WH, Tan KL, Babaei MA, Cheah PS, Ling KH. MicroRNAs and intellectual disability (ID) in Down syndrome, X-linked ID, and Fragile X syndrome. *Front Cell Neurosci*. 2013; 7:41.doi: 10.3389/fncel.2013.00041 [PubMed: 23596395]
- Vega Genome Browser 54: Homo sapiens. Chromosome summary - Chromosome. Vol. 21. Wellcome Trust Sanger Institute; p. 1-48.119,895data retrieved 16 May 2017
- Wang HH, Wang YC, Wu DW, Hung CS, Chen CY, Lee H. Targeting insulin-like growth factor-binding protein-3 by microRNA-125b promotes tumor invasion and poor outcomes in non-small-cell lung cancer. *Tumour Biol*. 2017; 39:1010428317694316.doi: 10.1177/1010428317694316 [PubMed: 28378642]
- Wang LQ, Chen G, Liu XY, Liu FY, Jiang SY, Wang Z. microRNA.802 promotes lung carcinoma proliferation by targeting the tumor suppressor menin. *Mol Med Rep*. 2014; 10:1537–42. DOI: 10.3892/mmr.2014.2361 [PubMed: 24994111]
- Wang PY, Sun YX, Zhang S, Pang M, Zhang HH, Gao SY, et al. Let-7c inhibits A549 cell proliferation through oncogenic TRIB2 related factors *FEBS Lett*. 2013; 587:2675–2681.
- Wu D, Zhou Y, Pan H, Qu P, Zhou J. microRNA-99a inhibits cell proliferation, colony formation ability, migration and invasion by targeting fibroblast growth factor receptor 3 in prostate cancer. *Mol Med Rep*. 2015; 11:1469–1475. DOI: 10.3892/mmr.2014.2792 [PubMed: 25352177]
- Yu SH, Zhang CL, Dong FS, Zhang YM. miR-99a suppresses the metastasis of human non-small cell lung cancer cells by targeting AKT1 signaling pathway. *J Cell Biochem*. 2015; 116(2):268–76. 2015. DOI: 10.1002/jcb.24965 [PubMed: 25187230]
- Yuan F, Wang W. microRNA-802 suppresses breast cancer proliferation through downregulation of FoxM1. *Mol Med Rep*. 2015; 12:4647–51. DOI: 10.3892/mmr.2015.3921 [PubMed: 26080894]
- Zhang W, Liu H, Liu W, Liu Y, Xu J. Polycomb-mediated loss of microRNA let-7c determines inflammatory macrophage polarization via PAK1-dependent NF- κ B pathway. *Cell Death Differ*. 2015; 22:287–297. DOI: 10.1038/cdd.2014.142 [PubMed: 25215948]
- Zhang X, Ma X, An H, Xu C, Cao W, Yuan W, Ma J. Upregulation of microRNA-125b by G-CSF promotes metastasis in colorectal cancer. *Oncotarget*. 2017; 2017. doi: 10.18632/oncotarget.16892
- Zhao S, Gong Z, Zhang J, Xu X, Liu P, Guan W, et al. Elevated serum microRNA Let-7c in moyamoya disease. *J Stroke Cerebrovasc Dis*. 2015; 24:1709–1714. DOI: 10.1016/j.jstrokecerebrovasdis.2015.01.041 [PubMed: 26070522]
- Zhao Y, Pogue AI, Lukiw WJ. MicroRNA (miRNA) signaling in the human CNS in sporadic Alzheimer's disease (AD) - novel and unique pathological features. *Int J Mol Sci*. 2015; 16:30105–30116. DOI: 10.3390/ijms161226223 [PubMed: 26694372]
- Zhao Y, Alexandrov PN, Lukiw WJ. Anti-microRNAs as novel therapeutic agents in the clinical management of Alzheimer's disease. *Front Neurosci*. 2016; 10:59. 2016. doi: 10.3389/fnins.2016.00059 [PubMed: 26941600]

Table 1
miRNAs encoded on human chr 21, location, Genbank Accession, function/disease association and references

micro RNA	chromosomal location/Genbank sequence	number of potential mRNA targets*	function/disease association	references
let-7c	chr21q21.1/NR_029480	~700	tumor suppressor/arsenite-induced, gastric, lung and colorectal cancers; Moyamoya disease	Lee and Dutta 2007; Lukiw 2007; Sethi and Lukiw 2009; Wang et al., 2013; Cappuzzo et al., 2014; Crowley et al., 2014; Jiang et al., 2014; Zhang et al., 2015; Zhao et al., 2015; Regazzo et al., 2016); http://www.genecards.org/cgi-bin/carddisp.pl?gene=MIRLET7C&keywords=mir-let7c;
miRNA-99a	chr21q21.1/NR_029514.1	~665	lung cancer, multiple myeloma, head and neck squamous cell carcinoma, anaplastic thyroid and prostate cancer	Feng et al., 2015; Hou et al., 2015; Huang et al., 2015; Wu et al., 2015; Yu et al., 2015; Regazzo et al., 2016; http://www.genecards.org/cgi-bin/carddisp.pl?gene=MIR99A&keywords=mir-99a;
miRNA-125b-2	chr21q21.1/NR_029694.1	~900	NF-kB inducible miRNA; involved in astrogliosis, glial cell proliferation, Alzheimer's disease (AD), age-related macular degeneration (AMD), breast, gastric, gallbladder, lung, squamous cell and colorectal carcinoma, intellectual disabilities, glioma, glioblastoma; status epilepticus	Lukiw 2007; Pogue et al., 2010; Risbud and Porter 2013; Siew et al., 2013; Siew et al., 2013; Feng et al., 2015; Ferlazzo et al., 2016; Moss et al., 2016; Regazzo et al., 2016; Wang et al., 2017; Zhang et al., 2017; http://www.genecards.org/cgi-bin/carddisp.pl?gene=MIR802&keywords=mir-802
miRNA-155	chr21q21.3/NR_030784.1	~700	NF-kB inducible miRNA; adenocarcinoma, Alzheimer's disease (AD); age-related macular degeneration (AMD), B-cell lymphoma, bacterial pneumonia, peritonitis, colitis, squamous cell carcinoma, Down's syndrome (DS), hepatic fibrogenesis, bladder cancer, multiple sclerosis (MS), status epilepticus	Pogue et al., 2010; Li et al., 2012; Lukiw et al., 2012; Maciotta et al., 2013; Risbud and Porter 2013; Devier et al., 2015; Bofill-De Ros et al., 2015; Asim et al., 2015; Hill et al., 2015; Siew et al., 2013; Feng et al., 2015; Ferlazzo et al., 2016; Moss et al., 2016; Regazzo et al., 2016; Lu et al., 2017; Luts et al., 2017; Mikamori et al., 2017; http://www.genecards.org/cgi-bin/carddisp.pl?gene=MIR155&keywords=mir-155
miRNA-802	chr21q22.12/NR_030414.1	~665	breast cancer, Down's syndrome and DS murine models, biliary hyperplasia type 2 diabetes, cholesteatoma, osteosarcoma	Cao et al., 2013; Li and Qin 2014; Wang et al., 2014; Higuchi et al., 2015; Yuan et al., 2015; Bofill-De Ros et al., 2015; Church et al., 2016 www.genecards.org/cgi-bin/carddisp.pl?gene=MIR802&keywords=mir-802
summary	chr21q21.1-chr21q21.3/various	~3630	a surprisingly broad range of human diseases including many cancers and neurological disorders such as DS, AD, AMD and MS	multiple (see text and above)

Down syndrome (DS) or trisomy 21 (T21) results from a gene dosage imbalance that translates into a surprisingly broad clinical spectrum. DS is the most common genetic cause of intellectual disability attributable to a naturally-occurring imbalance in gene dosage - a major objective in the study of DS is the identification of functional genetic elements that impact alterations and variations in the DS phenotype. Indeed DS is a primary

human model for studying imbalances in gene dosage and provides a unique opportunity to elucidate the molecular and pathogenic consequences of extra chromosomal copies; note that: (i) DS is also associated with multiple other serious age-related human maladies (see text and Table 1 column function/disease association); (ii) the majority of the disease associations listed above are the result of the mis-regulation of let-7c, miRNA-99a, miRNA-125b, miRNA-155 and/or miRNA-802 abundance and expression; (iii) all 5 chr21-encoded miRNAs are located within the relatively narrow domain on the long arm of chr21 from chr21q21.1 to chr21q21.3; (iv) all 5 chr21-encoded miRNAs have strong genome-wide regulatory effects; (v) miRNA-99a, miRNA-125b and miRNA-155 are inducible and under NF- κ B regulatory control (Hill et al., 2015; unpublished observations); and (vi) at least 3 of these miRNAs encoded on chr21 are significantly increased in expression in AD and/or DS (miRNA-125b, miRNA-155 and miRNA-802; Lukiw 2007; Li et al., 2012; Devier et al., 2015; Zhao et al., 2015; Castro et al., 2017). Interestingly, of the 2650 human miRNAs so far identified, only about 35-40 are highly expressed in the human brain and retina and of these miRNA-125b and miRNA-155 are encoded on chr21 (Hattori et al., 2000; Li et al., 2012; Zhao et al., 2015; Antonarakis, 2017);

* the number of potential miRNA-mRNA interactions was assessed using the MicroCosm Targets Version 5 (miRBase; EMBL-EBI) algorithm.